Participants were randomized in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at 2.4 milligrams or placebo for an initial 72 weeks as part of a longer 240-week trial designed to ...

we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks.

Participants were randomly assigned to receive once-weekly subcutaneous semaglutide 2.4 mg or placebo for 240 weeks (534 and 266 patients, respectively). The primary end points of resolution of ...

The frequency of blurred vision and visual impairment was relatively high with both formulations of semaglutide; adverse drug events related to the retina were more common with subcutaneous ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration (FDA) has accepted for review ...

Subcutaneous semaglutide was initiated in all participants at a dose of 0.25 mg given once weekly, and the dose was titrated every 4 weeks to 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg (target dose ...